4P Pharma, SATT AxLR and IBMM have concluded a co-development agreement Montpellier, December 1st 2015 In the context of an innovative medical drug development project for the treatment of cancers, called “Imiqualines”, the oncology-pharmaco-chemical and pharmaco-toxicological team of IBMM, SATT AxLR and 4P Pharma have concluded a co-development maturation agreement with a licensing&hellip